EU vote could put gene-based treatments outside gene therapy safety rules

The EU’s pharmaceutical overhaul would classify medicines used to treat infectious diseases as vaccines, then exclude those vaccines from the gene therapy category. That is the wording in the Council’s text.

The distinction has consequences. Gene therapy products made with synthetic or recombinant nucleic acids fall under specific safety rules. Infectious-disease vaccines are carved out of that definition, meaning those gene-therapy-specific requirements do not automatically apply. And the vaccine definition now expressly covers treatment, not just prevention.

This doesn’t mean the products face no testing. It means they can fall under a different set of rules. With Parliament due to vote November 25, the question is why this broader exemption is being written into EU law and how many products could qualify.

https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=consil:ST_12263_2026_INIT

https://oeil.europarl.europa.eu/oeil/cs/procedure-file?reference=2023%2F0132%28COD%29

https://www.consilium.europa.eu/en/press/press-releases/2026/09/28/pharma-package-council-adopts-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/

Got a news tip or correction? Let us know

If you got something out of this, please chip in to keep this site running, or subscribe to go ad-free.

1 view